Literature DB >> 33361584

Identification of potential serum biomarkers for simultaneously classifying lung adenocarcinoma, squamous cell carcinoma and small cell carcinoma.

Jiangqing Yu1,2, Fen Du1,3, Liping Yang4, Ling Chen3, Yuanxiang He5, Ruijin Geng3, Le Wu1,3, Baogang Xie1,3.   

Abstract

BACKGROUND: Histological subtypes of lung cancer are crucial for making treatment decisions. However, multi-subtype classifications including adenocarcinoma (AC), squamous cell carcinoma (SqCC) and small cell carcinoma (SCLC) were rare in the previous studies. This study aimed at identifying and screening potential serum biomarkers for the simultaneous classification of AC, SqCC and SCLC. PATIENTS AND METHODS: A total of 143 serum samples of AC, SqCC and SCLC were analyzed by 1HNMR and UPLC-MS/MS. The stepwise discriminant analysis (DA) and multilayer perceptron (MLP) were employed to screen the most efficient combinations of markers for classification.
RESULTS: The results of non-targeted metabolomics analysis showed that the changes of metabolites of choline, lipid or amino acid might contribute to the classification of lung cancer subtypes. 17 metabolites in those pathways were further quantified by UPLC-MS/MS. DA screened out that serum xanthine, S-adenosyl methionine (SAM), carcinoembryonic antigen (CEA), neuron-specific enolase (NSE) and squamous cell carcinoma antigen (SCC) contributed significantly to the classification of AC, SqCC and SCLC. The average accuracy of 92.3% and the area under the receiver operating characteristic curve of 0.97 would be achieved by MLP model when a combination of those five variables as input parameters.
CONCLUSION: Our findings suggested that metabolomics was helpful in screening potential serum markers for lung cancer classification. The MLP model established can be used for the simultaneous diagnosis of AC, SqCC and SCLC with high accuracy, which is worthy of further study.

Entities:  

Keywords:  1H-NMR; Subtypes of lung cancer classification; UPLC-MS/MS; metabolomics; serum biomarkers

Year:  2021        PMID: 33361584     DOI: 10.3233/CBM-201440

Source DB:  PubMed          Journal:  Cancer Biomark        ISSN: 1574-0153            Impact factor:   4.388


  3 in total

1.  Application of Surface-Enhanced Raman Spectroscopy in the Screening of Pulmonary Adenocarcinoma Nodules.

Authors:  Bowen Peng; Huan Yan; Runrui Lin; Gang Yin
Journal:  Biomed Res Int       Date:  2022-06-23       Impact factor: 3.246

2.  Assessing the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio in Stage I Non-Small-Cell Lung Cancer with Complete Resection.

Authors:  Wei Liu; Tiantian Zhang; Li Li; Jue Zou; Chunhua Xu
Journal:  Can Respir J       Date:  2022-06-22       Impact factor: 2.130

3.  Serum tumor markers level and their predictive values for solid and micropapillary components in lung adenocarcinoma.

Authors:  Zhihua Li; Weibing Wu; Xianglong Pan; Fang Li; Quan Zhu; Zhicheng He; Liang Chen
Journal:  Cancer Med       Date:  2022-03-14       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.